Gorlin syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Clinical Trials

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Condition:   Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome PatientsInterventions:   Drug: Placebo;   Drug: LDE225;   Drug: LDE225 0.25%;   Drug: LDE225 0.75%Sponsors:   Novartis Pharmaceuticals;   NovartisCompleted - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2009 Category: Research Source Type: clinical trials